What is the Frontotemporal Dementia Market Outlook?

What is the Frontotemporal Dementia Market?

DelveInsight’s ‘Frontotemporal Dementia Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the Frontotemporal dementia (FTD), historical and forecasted epidemiology as well as the Frontotemporal Dementia market trends in the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

What is the Frontotemporal Dementia Market Size Report?

The Frontotemporal Dementia market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted 7MM Frontotemporal Dementia market size from 2019 to 2032. The Report also covers current Frontotemporal Dementia treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

What are Frontotemporal Dementia and its treatment?

FTD is a term used to describe a group of neurocognitive disorders that encompass progressive dysfunction in executive functioning, behavior, and language. There are three types of frontotemporal disorders (FTD): behavioral variant frontotemporal dementia (bvFTD), primary progressive aphasia (PPA), and movement disorders. FTD occurs when brain cells in the frontal or temporal lobes die due to the build-up of abnormal proteins, leading to abnormal brain function, and more cell deaths result in brain atrophy. Many possible symptoms can result, including unusual behaviors, emotional problems, trouble communicating, difficulty with work, or difficulty with walking. FTD can be hard to diagnose as it displays clinical symptoms that can be mistaken for other dementias or psychiatric disorders. The average time from symptom onset to accurate diagnosis is about 3.6 years.

Diagnosis of FTD currently includes Imaging and blood or cerebrospinal fluid studies. A ‘definite’ diagnosis of FTD is still based on neuropathology confirmation postmortem. Diagnostic markers currently used for FTD include imaging and blood or cerebrospinal fluid studies. They may best serve a diagnostic role when used in a multimodal approach to achieve a ‘definite’ diagnosis of FTD in the living patient as soon as possible. The management of problematic behaviors in FTD with mainly sparse case reports and case series detailing their effectiveness lacks the study quality. The main purpose of nonpharmacological interventions—described below—is to prevent disruptive behaviors, provide symptom relief, and lessen caregiver distress.

What are the Frontotemporal Dementia Emerging Drugs?

AL001: Alector

It is monoclonal antibody designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease, and Parkinson’s disease. Company has initiated phase III trial for FTD-GRN mutation and undergoing phase II trials for FTD-C9orf72 to test its safety and efficacy towards FTD.

PBFT02: Passage Bio

It is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the granulin (GRN) gene to a patients cells. The company has an active IND from the FDA and approved CTAs in multiple countries, which allows them to proceed with multi-center, open-label, single-arm Phase I/II clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN.